

Contents

<i>List of tables</i>	vi
<i>List of figures and boxes</i>	viii
<i>Acknowledgements</i>	ix
<i>Preface</i>	x
1. Mergers and remedies in the EU: an overview	1
2. The literature on merger remedies	9
3. Classification of merger remedies	37
4. Methodology for assessment of mergers and remedies	44
5. Structure and competitive process in paper and board markets	74
6. Assessment of remedies adopted by the EC in paper mergers	93
7. Structure and competitive process in pharmaceuticals markets	134
8. Assessment of remedies adopted by the EC in pharmaceuticals mergers	179
9. Conclusions and recommendations	238
<i>References</i>	253
<i>Index</i>	263

Tables

1.1	Trends in merger remedies	4
1.2	Distribution of mergers and remedies across broad sectors	6
1.2(a)	The case study industries	7
3.1	EC remedy types, 1996–2000	38
3.2	An alternative classification of EC remedy types, 1991–2005	38
3.3	Remedy by type of competition concern	39
3.4	Remedies by theory of harm	39
5.1	NACE 21 pulp, paper and paper products	75
5.2	Merger interventions classified by markets in which remedies imposed	76
5.3	Paper production and consumption by grade, 2001: CEPI classification	77
5.4	Some indicators of structure and performance	79
5.5	Geographical distribution of production by broad product category, leading countries' shares	80
5.6	European firms in the world's top 100	81
5.7	Capacity utilization in the graphic paper sector	84
5.8	Main mergers/JV proposals by the largest firms	85
5.9	Leading market shares and concentration in the graphic paper sector	87
5.10	Leading market shares and concentration in the tissues sector	89
5.11	Leading ten market shares in packaging	90
6.1	Dimensions of market, 1994	95
6.2	Estimates of price elasticities for toilet tissue	96
6.3	Number and size distribution of sellers	98
6.4	Advertising spends, 1994 (£000)	100
6.5	Derivation of relative prices in the three segments	103
6.6	Imputing the own-price elasticities	104
6.7	The required comparisons	107
6.8	Theoretical mark-ups pre- and post-merger	109
6.9	Simulated price increases according to diversion ratio	111
6.10	Imputed market shares for individual private labels	112
6.11	Simulation results for toilet tissues	113

6.12	Simulation results for kitchen towels and facials	114
6.13	Actual price outcomes	115
6.14	Actual market shares	117
6.15	Market structure in 2000 (by volume)	120
6.16	The required comparisons	124
6.17	Simulated price increases	130
7.1	NACE 24.4 manufacture of pharmaceuticals, medicinal chemicals and botanical products	135
7.1 (a)	Anatomical therapeutic chemical classification system	136
7.1 (b)	Typical drug groups as used in the industry (for example, company reports)	136
7.2	Merger interventions classified by drug type for which remedies were imposed	137
7.3	Size of the world's market in pharmaceuticals, 1985–2002	140
7.3 (a)	The member states, the USA and Japan	141
7.4	The world's 50 largest pharmaceutical firms, 2002	142
7.5	The world's top selling drugs, 2002	144
7.6	Main mergers by the largest firms	145
7.7	The impact of mega-mergers on Europe's top ten in 2002	147
7.8	US FDA approval timescale	152
7.9	Regulatory success rates for pipeline products	153
7.10	Mean number of competitor products per molecule by country	164
7.11	Importance of elasticities – market share analysis compared with basic simulation (using PCAIDS)	173
8.1	Pharmaceuticals mergers, markets and simulations	180
8.2	Market shares for selected CCR markets	185
8.3	Simulated effect of allowing merger of BM/Roche CCS businesses	187
8.4	Market shares in immediate-release analgesics in Sweden	192
8.5	Simulated effect of allowing merger and accepted remedies for PU/Monsanto in immediate-release analgesics in Sweden	193
8.6	Commercial and scientific names of main products	209
8.7	AstraZeneca: chirocaine simulations	212
8.8	Market shares in anti-virals (excluding HIV)	221
8.9	Simulated effects of unremedied GWSB merger in anti-virals (excluding HIV)	222
8.10	Market shares in topical anti-virals	223
8.11	Simulated effects of unremedied GWSB merger in topical anti-virals	224
9.1	Summary assessment of case study mergers and remedies	241

Figures and boxes

FIGURES

1.1	EC mergers and remedies (1990–2006)	4
6.1	Relationship between price and the HHI index across member states	122
6.2	Imputed price–cost margins versus the HHI index (subsample)	123
8.1	Linkages in market for ‘stupefying active substances’ in France	198
8.2	Linkages in market for ‘stupefying active substances’ in France, Belgium and the rest of the world	199

BOXES

3.1	Remedies in context	40
4.1	Proof of equation (4.7)	59